Via Reuters: A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday. The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of …
Read More »